Objective: To evaluate the efficacy of visual inspection with acetic acid (VIA) in the early detection of cervical cancer and compare it with the Pap smear. Study Design: This was a cross-sectional study conducted over a period of 3 months. A total of 316 patients who attended the Gynecology Outpatient Department of Era's Lucknow Medical College and Hospital, fulfilled the inclusion criteria, and gave their informed consent were included. Results: VIA was found positive in 38 patients (12.6%). Pap smear was positive in 31 patients (10.3%). Twenty-eight patients had a positive VIA and a positive Pap smear, 3 had a negative VIA and a positive Pap smear, 10 had a positive VIA and a negative Pap smear, and 34 had a negative VIA and a negative Pap smear. Conclusion: The sensitivity of VIA and the Pap smear was found to be nearly equal, 93.3 and 93.8%, respectively. The Pap smear was found to be more specific than VIA, i.e., 72.9 versus 60%. In terms of test accuracy, the Pap smear was found to have greater test accuracy, i.e., 77.3 versus 66.7% for VIA.

Keywords:
Pap smear, Visual inspection with acetic acid, The Bethesda System, Cervical cancer screening
1.
Jeronima J, Morales O, et al: Visual inspection with acetic acid for cervical cancer screening outside of a low resource setting. Rev Panam Salud Publica 2005;17:1-5.
2.
Saleh HS: Can visual inspection with acetic acid be used as an alternative to Pap smear in screening cervical cancer? Middle East Fertil Soc J 2014;19:187-191.
3.
Rahatgaonkar V: VIA in cervical cancer screening. IOSR J Dent Med Sci 2012;1:1-4.
4.
Naaz U, Naseeb S, et al: Concordance between visual inspection with acetic test and Pap smear in detection of cervical cancer. J Surg Pakistan 2016;21:18-21.
5.
Ibrahim A, et al: Cervical cancer screening in primary health care setting in Sudan: a comparative study of visual inspection with acetic acid and Pap smear. Int J Womens Health 2012;4:67-73.
6.
Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al: Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol 2015;136:178-182.
7.
Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S: A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005;89(suppl 2):S4-S12.
8.
Denny L, Kuhn L, De Souza M: Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005;294:2173-2181.
9.
Vadehra K, Jha R: Visual inspection using acetic acid and Pap smear as a method of cervical cancer screening. J Inst Med 2006;28:36-40.
10.
Bhattacharyya AK, et al: Comparative study between Pap smear and visual inspection with acetic acid (VIA) in screening of CIN and early cervical cancer. J Midlife Health 2015;6:53-58.
11.
Omole-Ohonsi A, Aiyedun TA, Umoru JU: Diagnostic accuracy of VIA compared to Pap smears cytology in detecting premalignant lesions of the cervix. Afr J Med Health Sci 2013;12:25-30.
12.
Harshini V, Bhandary A, Thungha S: Comparison between Pap smear and VIA as a screening tool for cervical lesions. Indian J Pharm Biol Res 2013;1:55-60.
13.
Kitchener HC, Castle PE, Cox JT: Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006;24(suppl 3): S3/63-70.
14.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11. Lyon, International Agency for Research on Cancer, 2013.
15.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-314.
16.
Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellström A, Elfgren K, et al: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-1466.
17.
United States Food and Drug Administration: FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV, 2014 (accessed on March 20, 2015). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.
18.
Ankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, et al: HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394.
19.
Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group: Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-2168.
20.
Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, Bosch FX, Goldie SJ: Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008;99:230-238.
21.
Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, Goldie SJ: Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2012;130:2672-2684.
22.
World Health Organization: Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, World Health Organization, 2013.
23.
Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL, et al: Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 2001;98:441-444.
24.
Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, et al: Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-2168.
25.
Longatto Filho A, et al: Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology. Virchows Arch 2012;460:577-585.
26.
Shastri SS, et al: Effect of VIA screening by primary health workers J Natl Cancer Inst 2014;106.
27.
Sarion LO, et al: Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J Med Screen 2005;12:142-149.
28.
Syrjänen K: Value of conventional Pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among Latin American women <35 and ≥35 years of age: experience from the Latin American Screening Study. Acta Cytol 2008;52:641-653.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.